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Results: A total of 325 IMRT treatment verifications have been 
performed (315 RA), with more than 700 portal images analyzed. 
Although we use a quite restrictive protocol (local gamma index) the 
average number of points that passed the mentioned criterion has 
been 95.1% (range: 83.5 – 99.9,std dev: 4%). The worse cases results 
have been found in IMRT static fields (like mantle type fields), in 
complex cases (non-coplanar 6 arcs treatment, very large fields even 
exceeding the detector size) and in RA plans with a large number of 
arcs in which the acquired images show a pattern of regions with large 
portions shielded.  We use Portal Dosimetry in each IMRT plan prior to 
treatment due mainly to the characteristics of the detector, but it has 
to be used in conjunction with other dosimetric systems. On one side 
are the limitations of the prediction algorithm, and on the other it is 
difficult to establish the acceptance levels for gamma analysis results 
especially for RA where the whole arc is acquired in one image. 
Conclusions: Portal Dosimetry is being used in routine in IMRTpre-
treatment patient-specific verifications. For most of the cases pass 
rates are quite high, but another two systems are used in conjunction 
in order to decide the acceptability of the plan. Specific acceptance 
levels guidances provided by vendor would be very helpful to users. 
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Purpose/Objective: Total body irradiation treatments are usually 
checked with in-vivo dosimetry measurements. In our institution we 
use a diodes-based in-vivo dosimetry system, composed of diodes, 
electrometer and software. A single failure in one of the components 
may make the system unusable. We aimed to evaluate Gafchromic 
EBT2 radiochromic film (International Specialty Products) as a backup 
system for diodes to perform in-vivo dosimetry for total body 
irradiation treatments. 
Materials and Methods: EBT2 films readings were compared to a 
Farmer 30013 chamber (PTW) and EDP-15 diodes (IBA) in a solid water 
phantom, in TBI conditions: 6 MV photon beam (Varian 2100 linac), 
40x40 cm2 field, SSD=315 cm, 1 cm PMMA beam spoiler. Films were 
located at the phantom surface, under a 1 cm bolus slab. Diodes were 
also at surface and ionization chamber was situated at phantom mid-
plane (9 cm depth). Two films were irradiated each time. EBT2 films 
were tested for post-irradiation time influence, linearity, accuracy 
and reproducibility. We also measured attenuation of bolus+film and 
assessed the influence of interruptions during irradiation. A film inside 
the phantom measured a PDD curve. Red channel calibration was used 
to read the films. The method was clinically tested in three patients: 
a 2x2 cm2 piece of film was affixed to patient's skin (at abdomen) 
below a 1 cm bolus slab. Film reading was converted to mid-plane 
dose and compared with diode readings. 
Results: We found that films response remains stable after around 24 
h. Dose linearity was excellent in the range 10-200 cGy. PDD 
measurement showed a dose value at mid-plane of 79.3% of maximum 
dose, while PDD measured with ionization chamber showed a value of 
80.4%. Film dose readings were within 3% respect to chamber dose 
values (mean -1.6%), except for one film (6%). Difference between 
film and diodes were within 4.6% (mean -3.2%), except for one film 
(7.5%). Film reproducibility was within 2% (10 films). Since one of the 
films showed a very different dose from the mean value (6%), 
reproducibility would drop to 1.4% if this film was not considered. No 
significant influence of interruption time was detected for an 
interruption time up to 6 min. Bolus slab and EBT2 film produced an 
attenuation of 2.5% at phantom mid-plane. Results from the three 
patients studied showed a deviation of 2.5%, 3.1% and 2.0% between 
EBT2 films and diodes. 
Conclusions: We developed a practical method to use EBT2 film as a 
backup system for diodes in TBI in-vivo dosimetry. Mean film dose 
readings differed from diodes less than 3.5%, in phantom and clinical 
conditions. EBT2 films are an adequate in-vivo dosimeter provided 
some precautions are taken: films should be read 24 h after 
irradiation and we recommend using at least 2 pieces of film for each 
location, and set up the bolus slab with film at a different position 
each session to diminish the attenuation effect. 
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Purpose/Objective: TomoDirectTM (TD) is a non-rotational treatment 
option implemented on the TomoTherapy Hi-Art system (Accuray, 
Inc., Sunnyvale, CA). It stands as an alternative to conventional linac 
system, allowing to deliver IMRT treatments with a static gantry 
position. With the introduction of TD new potentialities for the 
treatment of the whole breast are now available. Since some 
protocols recommended to systematically check the absorbed dose 
delivered in new treatment techniques to a patients’ sample 
implementing in-vivo dosimetry protocol, we decided to study the 
effectiveness of MOSFET (TN-502 RDM-H standard microMOSFET 
Thomson & Nielsen, Ottawa, ON Canada) as in-vivo dosimeters during 
TD treatment of breast cancer. 
Materials and Methods: The MOSFETs were calibrated against an 
ionization chamber type Exradin A1SL (Standard Imaging, Middleton, 
WI) using a modulated TD beam calculated on PMMA phantom. The 
entrance and exit dose calibration factors were determined in a solid 
water phantom positioning the MOSFET with the required 
hemispherical brass build-up cup. To verify the MOSFET effectiveness 
during in vivo dosimetry, dose measurements were performed on 
whole breast treatment plans created using TD two opposed 
tangential beams technique on an anthropomorphic Rando female 
thorax phantom (Phantom Laboratory, Salem, New York). 
Measurements were performed positioning MOSFET at the medial side 
on a point coincident with the red laser at 5 cm from radiopaque 
alignment marker and at the lateral side on the same defined 
reference point. This process was repeated several times to evaluate 
the reproducibility and accuracy of MOSFET measurements during 
treatment on a Tomotherapy Hi-Art unit. In vivo dosimetry was then 
performed on a total of 15 whole breast patients using the same 
procedure. Discrepancies between measured and calculated values for 
TD treatments have been evaluated. 
Results: The reproducibility of the MOSFET response is found to be 
better than 2.5% for the doses normally delivered to the patients. The 
difference between the MOSFET measured dose on Rando phantom 
and the planned dose at each point was less than 4%, with an average 
of -0.8 %± 1.7%. In vivo dose measurements show that the dose 
difference between MOSFET results and the TPS calculations was on 
average -0.7%, ranging from -4.7% to 4.8% with a standard deviation of 
the measurements of each patient less than 3%. 
Conclusions: In conclusion, MOSFET detectors are suitable for routine 
TD dose verification. 
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Purpose/Objective: The aim of this study is to develop a novel dose-
verification method for intensity-modulated radiotherapy (IMRT) that 
expands upon the traditional DTA (extended DTA) by adding 
displacement directions to the distance difference. 
Materials and Methods: The extended DTA was acquired by measuring 
the distance between the isodose lines obtained from theTreatment 
Planning System (reference isodose line) and the film dosimetry 
(evaluation isodose line) (EDR2 Films: EastmanKodak Company;) of the 
prostate IMRT case. The extended DTA is the difference between the 
points at which the reference and evaluation isodose line intersect 
with a straight line after every 10° with respect to the origin. 
Furthermore, the distance of the difference was determined as both 
'negative' and 'positive' if the evaluation isodose lines were both inside 
and outside the reference isodose lines, respectively. This latter 
assessment is useful because some reference isodose lines show low 
and high doses. The extended DTA was represented by 2D difference 
maps that use cylindrical projection. These maps show the angle in 
the horizontal axis, the dose in the vertical axis and the distance of 
difference (in millimeters) with the color scale. The extended DTA 
was performed by an in-house program and compared with the gamma 
analysis and the DTA using an OmniPro ImRT (IBA Dosimetry). The 
criterion value used for the gamma analysis and the DTA was 2mm3%, 
2mm. DTA was 2mm3%, 2mm. The extended DTA was calculated using 
max dose and 100%, 97%, 95%, 93%, 90% and 80% of the isodose lines. 
Results: The extended DTA in the 2D difference map showed a value 
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of about 5 to 38 mm to the plus direction in the range of 60 to 330 
degrees of the maximum dose and 100% of the isodose lines(Fig.1). On 
the other hand, a range of about 310 degrees in 97%, 95% and 93% of 
the isodose lines showed the value of about 10mm to a plus direction. 
The extended DTA for 97% to 80% of the isodose lines showed a value 
of 1 mm to the plus direction at 270 degrees (the rectum side). 
Although the extended DTA showed a large value (maximum dose and 
100% of the isodose lines), this was considered a cause for concern, 
because the dose slope was small and the interval of the isodose lines 
was small. The pass rate of the gamma values is 98.8%. Therefore, a 
clear error was undetectable. Therefore, gamma analysis and DTA are 
both useful tools, but they do not allow to evaluate the displacement 
direction of isodose lines in the arbitrary position on dose distribution. 
On the other hand, the extended DTA includes a 2D position and a 
direction for the dose difference, so it was able to detect the risk of 
overdose and under-dosefor the target and OAR. 
 
 
Conclusions: This study proposes a novel method—extended DTA—that 
incorporates the concept of displacement direction in DTA and might 
be an effective method for evaluating dose differences and directions 
in radiotherapy.  
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Purpose/Objective: To compare the secondary radiation doses 
following intensity-modulated radiotherapy (IMRT), Rapidarc and 
Tomotherapy(TOMO) in patients with lung cancer by using a 
radiophotoluminescence glass dosimeter (RPLGD) which is newly 
introduced, as a substitution of themoluminescence dosimeter (TLD) 
or other. 
Materials and Methods: Patient data and treatment planning. We 
randomly selected five patients with lung cancer who were to be 
treated with IMRT at our institution. All of these patients had 
undergone treatment planning CT scans (Brilliance CT Big Bore 
Oncology; Philips Medical System, The Netherlands) of the chest for 
identification of targets and normal neighboring organs. An Eclipse 
(Varian Medical Systems, Palo Alto, CA, USA) and Hi-Art 
(TomoTherapy, Madison, WI, USA) planning system were used to plan 
IMRT, Rapidarc and TOMO for five patients. The patient group is 
consists of three male and two female patient. The range of age is 
from 56 to 71 years old as average age of 67. All patients are stage III 
of non small cell lung cancer (NSCLC) cases and PTV volumes are 
varied from 210 to 890 cc. Measurement of secondary dose during 
IMRT, VMAT and Tomotherapy treatment. Secondary radiation was 
assessed by measuring the ionization of the photon beam (6MV) as a 
function of distance from the iso-center. These measurements were 
performed using two RPLGDs set at distances 20, 35, 50, 65 and 80 cm 
from the beam iso-center on a solid phantom. Secondary photon doses 
were measured using a RPLGD on the surface of couch table; thus, the 
secondary dose, measured at various distances from the isocenter, 
was the maximum possible dose at that distance and decreased with 
depth in the body. Therefore, the actual doses at certain body depths 
at each distance from the iso-center will be smaller than the 
measured doses. 
Results: The secondary dose per Gy (i.e., a treatment dose of 1 Gy) 
from IMRT for lung cancer, measured at 20 to 80 cm from the iso-
center ranged from 0 to 4 cGy which is higher when the PTV volume is 
large or measuring point closed to field edge. The secondary dose per 
Gy from RapidArc and TOMO ranged from 0 to 2 cGy and from 0 to 1 
cGy, respectively. It is indicating that TOMO is associated with a 
relatively small dose of secondary radiation than IMRT and RapidArc 
when the measuring point is around the field edge in spite of that 
tomotherapy has more than approximately 5 times lager monitor units 
than the other. In addition, RapidArc gives approximately 70% of 
monitor unit (MU) per fraction comparing to IMRT, indicating that 
RapidArc is associated with a smaller MU and short treatment time 
than other techniques. 
Conclusions: In conclusion, the secondary dose from TOMO is less than 
the secondary dose from conventional IMRT and RapidArc around the 
target area in spite of that tomotherapy has relatively higher monitor 
units(mu) than the other modalities. In another hand, it is found that 
rapidarc has shorter treatment time and MU than IMRT and TOMO. 
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Purpose/Objective: Intensity-modulated radiotherapy treatment is 
the most advanced technique for external beam photon radiotherapy. 
It allows todeliver a highly conformal dose to the patients. However, 
if on one hand the accelerator machine and the elaborate software 
dedicated to it allow to achieve such performances, on the other the 
problem of how to verify that the doses are irradiated within the 
planned limits of compatibility remains unsolved, because it demands 
stringent quality assurance. Generally 3D dose distributions obtained 
from a treatment planning system have to be verified by dosimetric 
methods. Usually, a comparison of two-dimensional calculated and 
measured data in several coplanar planes is performed. We propose 
the application of a GEM (Gas Electron Multiplier) detector. The 
particular configuration designed at the Frascati National Laboratories 
shows interesting properties which may overcome the limitations of 
conventional systems: low spatial resolution (> 2 mm), dose rate 
dependence, limited linearity, long acquisition times. 
Materials and Methods: Our GEM detector is a gas detector working as 
proportional counter. Gas mixture used is ArCO2 (70/30). The 
multiplication stages are made of three GEM foil. A GEM is made of at 
thin (50 μm) kapton foil, a copper cladding on each side, perforated 
with a high surface density of holes,each one acting as an electron 
multiplication channel. Each hole has a bi-conical structure with 
external (internal) diameter of 70 μm (50 μm) and a pitch of 140 μm. 
The detector has an anode consisting of 128 pads in a row. Each pad 
has an area of 0.5x0.5 mm, so that we can measure with a spatial 
resolution of 0.7 mm, which is the pitch between two successive pads. 
Moreover, equipping the detector of a linear motion system, we can 
obtain a dose measurement on a matrix of 128 x 128 points. Signals 
from the pad are digitalized and transferred through an ethernet 
cable on a PC, where they can be can be displayed and recorded. We 
performed a series of 2D dose measurements on the Eleckta Synergy 
clianical accelerator located in the Radiotherapy Department of the 
Tor Vergata University General Hospital. At the moment, our detector 
has an area of 10x10 cm, so we tested it on small fields. Data were 
acquired with the detector at the isocenter position (100 cm from the 
souce).  
Results: Results obtained show that our detector can measure very 
rapidly small X-ray dose fields with the resolution we expected. A 
single 1D beam profile can be taken in times minor than 100 ms. 
Moreover it shows an excellent linearity on dose rates ranging from 6 
to 400 MU/min. This has allowed us to have a dose measurement in a 
very wide range of values. 
